M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

INOVIQ (ASX:IIQ) is a biotechnology company developing new exosome-based diagnostics and therapeutics aimed at improving how cancer is detected and treated. The company has recently announced positive early-stage results from animal studies showing its CAR-exosome cancer therapy significantly reduced tumour growth, was safe, and improved survival in a breast cancer model. Ahead of Wholesale Investor’s Emergence 2026 Conference, INOVIQ Chief Executive Officer Dr Leearne Hinch joins The Stock Network’s Lel Smits to discuss what these results mean, how the technology works, and the next steps toward human trials. 1. What the latest study showed INOVIQ’s CAR-exosome therapy reduced tumour growth by more than 60% in a triple-negative breast cancer mouse study, with all treated animals surviving and no major safety concerns observed. In simple terms, what did this study show and why is it an important milestone for INOVIQ? 2. Why exosome therapies matter Unlike traditional cell therapies, INOVIQ’s CAR-exosomes are cell-free, designed to precisely target cancer cells while avoiding damage to healthy tissue. Why is this exosome-based approach potentially safer and easier to use than existing autologous T cell therapies? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
INOVIQ (ASX:IIQ): Advancing cancer treatment with next-generation exosome therapy
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5DNzNDRDE1NzhGODQzODI2

INOVIQ (ASX:IIQ): Advancing cancer treatment with next-generation exosome therapy

Prime Financial Group (ASX:PFG) is an integrated advice, capital and asset management group built around connected advice at scale. With around $1.9 billion in funds under management, a 27-year track record and a global footprint, Prime is positioned at the centre of several powerful structural tailwinds reshaping the Australian mid-market. Ahead of Wholesale Investor’s Emergence 2026 Conference, Partner – Sales & Distribution Darren Reed speaks with The Stock Network’s Lel Smits about where growth is coming from next. 1. Structural growth themes Intergenerational wealth transfer, private markets and alternatives, M&A and succession, technology-enabled advice and mid-market expansion are all accelerating. Which of these themes are currently driving the strongest growth for Prime, and how is the Group positioned to capture the opportunity? 2. Private markets and mid-market opportunity Capital is increasingly flowing into private markets, property and alternative assets, while mid-market businesses remain active across M&A and capital raising. How does Prime’s approach translate these trends into scalable earnings growth? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Prime Financial Group (ASX:PFG): How to invest in sports as a booming alternative asset class
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43MzBFRTZDMUM3OTY2RjQ4

Prime Financial Group (ASX:PFG): How to invest in sports as a booming alternative asset class

With global interest in innovative drug delivery and radiopharmaceuticals accelerating, Starpharma (ASX:SPL, US OTC:SPHRY) continues to advance its strategy of advancing its proprietary DEP® dendrimer platform through a combination of strategic partnerships and internal pipeline development. Following a series of high-level meetings at the J.P. Morgan Healthcare Conference in California, and the release of its Q2 FY26 quarterly results, Starpharma CEO & Managing Director Cheryl Maley joins The Stock Network’s Lel Smits to discuss recent milestones, the significance of its Genentech collaboration, and what lies ahead for the DEP® platform. 1. Strategic partnerships driving momentum During Q2 FY26, Starpharma continued execution of its recently announced strategic partnerships, including receiving an upfront payment of approximately AUD $8.3 million from Genentech. What progress has been made under the programs over the quarter? 2. Advancing radiopharmaceuticals and internal pipeline Starpharma continues to progress its DEP® HER2 radiopharmaceutical program toward a first-in-patient clinical study anticipated in 2026, alongside broader internal pipeline refinement and prioritisation. What key milestones should investors watch as these programs move closer to the clinic? 3. Business development and J.P. Morgan Healthcare Conference insights This year Starpharma engaged with existing and potential partners at the 44th Annual J.P. Morgan Healthcare Conference in California. How was the response to Starpharma and what were your main takeaways from participating? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Starpharma (ASX:SPL,US OTC:SPHRY):Strategic partnerships, balance sheet strength & pipeline momentum
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4xREVBMTg1ODg1M0JCQUE1

Starpharma (ASX:SPL,US OTC:SPHRY):Strategic partnerships, balance sheet strength & pipeline momentum

WAM Alternative Assets (ASX:WMA) is the only listed investment company on the ASX providing everyday investors access to a diversified portfolio of alternative assets typically reserved for institutions. Managed by Wilson Asset Management, WAM Alternative Assets focuses on delivering reliable income and capital growth with lower volatility than public markets. Ahead of Wholesale Investor’s Emergence 2026 Conference in Sydney, Portfolio Manager Nick Kelly joins The Stock Network’s Lel Smits to discuss how alternative assets can play a powerful role in portfolios during periods of market uncertainty. 1. Diversification beyond traditional markets WAM Alternative Assets invests across private equity, infrastructure, real estate, water and agriculture and private debt. Why are alternative assets increasingly important for investors looking to reduce volatility and diversify away from listed equities and bonds? 2. Identifying income resilience and capital protection Since Wilson Asset Management’s appointment in October 2020, WMA’s portfolio has delivered strong returns with significantly lower volatility than public markets. Can you give us an example of a successful alternative asset you've invested in and why it was so successful? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
WAM Alternative Assets (ASX:WMA): How to achieve diversification and resilient income when investing
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5CNzAzQzRDMkI3QThEQzZB

WAM Alternative Assets (ASX:WMA): How to achieve diversification and resilient income when investing

Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) is a clinical-stage biotechnology company developing a new class of synthetic anti-infectives designed to address the growing global threat of antibiotic-resistant superbugs. Over the past year, Recce’s share price has risen more than 40% on the back of the company progressing its clinical pipeline and securing regulatory and funding milestones. Ahead of Wholesale Investor’s Emergence 2026 Conference in Sydney, Chief Executive Officer James Graham joins The Stock Network’s Lel Smits to discuss Recce’s recent momentum, clinical progress and why antimicrobial resistance remains a major global health challenge. 1. Addressing a critical global health problem Antibiotic resistance is recognised by the World Health Organization as one of the biggest threats to global health. How does Recce’s synthetic anti-infective technology differ from traditional antibiotics, and why could this new approach be so important in treating resistant bacterial and viral infections? 2. Clinical progress, funding and value inflection points Recce has recently delivered a number of positive milestones, including strong efficacy data, new patent approvals, significant R&D rebates and eligibility for funding support of up to A$85 million. How do these developments strengthen Recce’s clinical pathway and position the company for potential value creation as trials advance? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Recce Pharmaceuticals (ASX:RCE): Advancing a new class of anti-infectives
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS45QzM0OUZCRDUyMTgwREVG

Recce Pharmaceuticals (ASX:RCE): Advancing a new class of anti-infectives

Shares in European Lithium (ASX:EUR, FRA:PF8, OTC:EULIF) are up more than 300% this year on the back of significant resource development activity, major funding inflows and continued advancement of high-value critical minerals assets including rare earths in Greenland and the largest lithium mine in Europe, based in Ukraine. Joining The Stock Network’s Lel Smits, Executive Chairman Tony Sage explains how European Lithium is building a globally diversified critical minerals portfolio, supported by a strengthening balance sheet and expanded drilling programs. 1. Transformational quarter backed by strong cash position European Lithium reported proceeds from the sale of Critical Metals Corp (NASDAQ:CRML) shares, followed by a major post-quarter transaction increasing combined European Lithium/Critical Metals Corp cash to around A$325 million. How do these funding outcomes support European Lithium’s strategy, and what does this mean for development of your core assets? 2. Drilling momentum at the Tanbreez Rare Earth Project, Greenland Tambereez is your biggest asset, located in Greenland and continues to produce high-grade drilling results. What makes Tanbreez such a unique rare earth project globally, and what are the next milestones investors should expect? 3. Expanding a multi-region critical minerals portfolio European Lithium is building scale across a number of key jurisdictions: Drilling and geological mapping underway in Austria, field crews and sampling programs active in Ireland, ongoing permitting in Ukraine, and strategic value growth through its shareholding in Critical Metals Corp. What are your immediate priorities, and what role does Critical Metals Corp play in creating value for shareholders? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
European Lithium (ASX:EUR): Building a critical minerals portfolio through resource milestones
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5DMkM0MjQ3OTgwQzBCMEZB

European Lithium (ASX:EUR): Building a critical minerals portfolio through resource milestones

As enterprises across Asia Pacific accelerate their shift toward AI-powered digital engagement, Vection Technologies (ASX:VR1, OTC:VCTNY, FRA: S1X) is expanding its footprint with a disciplined, earnings-accretive strategy. The Company has executed a binding offer to acquire Monogic Limited, a high-performing Hong Kong and Singapore digital marketing and brand experience agency, delivering strong EBITDA margins and deep relationships with major blue-chip clients. Joining The Stock Network’s Lel Smits, Lorenzo Biagi, Executive Director reveals how the acquisition strengthens Vection’s integrated digital transformation offering across immersive XR, AI and creative communications. 1. Transforming APAC digital engagement How does Monogic strengthen Vection’s digital engagement offering across APAC? 2. Integrated digital engagement platform What new solutions become possible by combining Monogic’s creative services with Vection’s XR and AI tech? 3. APAC expansion with blue-chip access How does Monogic’s presence in Hong Kong and Singapore accelerate Vection’s regional growth? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Vection Technologies (ASX:VR1, OTC:VCTNY, FRA:S1X): Accelerating APAC expansion
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5BRjY4NjdBRjA5RTdCMUMx

Vection Technologies (ASX:VR1, OTC:VCTNY, FRA:S1X): Accelerating APAC expansion

Venari Minerals NL (ASX:VMS) has reported another set of assay results from its October RC drilling program at the Red Mountain Lithium Project in Nevada, describing them as “outstanding”. The latest four drill holes delivered multiple thick, high-grade lithium zones and complete the full drilling dataset for the project’s central zone, paving the way for next month’s maiden Mineral Resource Estimate. Executive Director and CEO Matt Healy joins The Stock Network’s Lel Smits to discuss how these results strengthen Red Mountain’s scale potential and set up a catalyst-rich finish to the year. 1. Thick, high-grade lithium across the central zone This second batch of results includes standout intersections. How do these new hits build on the earlier results and what do they reveal about the continuity and quality of mineralisation in the central zone? 2. Complete dataset ahead of the maiden Resource With the central zone now fully drilled and these results confirming strong widths and grades, how does this finalised dataset shape your expectations heading into the maiden Mineral Resource Estimate next month, and what should investors look for as assays from the northern zone arrive? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Venari Minerals (ASX:VMS): Lithium hits add to Red Mountain dataset ahead of maiden Resource
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS41RjU0OTVCQThDNUUwQzBD

Venari Minerals (ASX:VMS): Lithium hits add to Red Mountain dataset ahead of maiden Resource

Pengana Private Equity Trust (ASX:PE1) gives investors rare access to global private markets through a single listed vehicle. Managed by Grosvenor Capital Management L.P., one of the world’s longest-operating alternative investment allocators, Pengana Private Equity Trust offers diversified exposure to private equity, private credit and opportunistic investments. Joining The Stock Network’s Lel Smits, Executive Director Adam Myers explains how Pengana Private Equity Trust opens the door to global private companies and long-term growth opportunities. 1. Accessing global private markets Pengana Private Equity Trust gives investors exposure to the kind of private equity usually reserved for institutions. How does Pengana Private Equity Trust make institutional quality private equity accessible for everyday investors? 2. Diversification across global private companies The Trust spans multiple strategies, sectors and geographies through Grosvenor’s platform. Which portfolio companies or themes best highlight Pengana Private Equity Trust’s global diversification? 3. Listed structure, long-term value and outlook Pengana Private Equity Trust combines private market exposure with ASX liquidity. Why is listed private equity an effective long-term addition to modern portfolios and what's your outlook for the year ahead? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Pengana Private Equity Trust (ASX:PE1): Accessing global private equity on ASX
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5EREU0QjZERDMzRDBGNTMz

Pengana Private Equity Trust (ASX:PE1): Accessing global private equity on ASX

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy